þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2013 |
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
LOUISIANA
|
72-0717400
|
|
(State or Other Jurisdiction of
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
Identification No.)
|
|
1925 W. Field Court, Suite 300
|
||
Lake Forest, Illinois
|
60045
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer þ
|
Accelerated filer o
|
Non-accelerated filer o
|
Smaller reporting company o
|
|||
(Do not check if a smaller reporting company)
|
Page
|
||||
3
|
||||
4
|
||||
5
|
||||
6
|
||||
7
|
||||
23
|
||||
28
|
||||
28
|
||||
30
|
||||
30
|
||||
30
|
||||
30
|
||||
30
|
||||
30
|
||||
30
|
||||
31 | ||||
EXHIBIT INDEX | 32 |
AKORN, INC.
|
||||||||
(In Thousands, Except Share Data)
|
||||||||
June 30,
2013
|
December 31,
2012
|
|||||||
(unaudited)
|
||||||||
ASSETS:
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$ | 58,412 | $ | 40,781 | ||||
Trade accounts receivable, net
|
57,707 | 51,017 | ||||||
Inventories, net
|
56,703 | 52,495 | ||||||
Deferred taxes, current
|
7,385 | 9,190 | ||||||
Prepaid expenses and other current assets
|
4,836 | 5,224 | ||||||
TOTAL CURRENT ASSETS
|
185,043 | 158,707 | ||||||
PROPERTY, PLANT AND EQUIPMENT, NET
|
81,033 | 80,679 | ||||||
OTHER LONG-TERM ASSETS:
|
||||||||
Goodwill
|
30,487 | 32,159 | ||||||
Product licensing rights, net
|
61,220 | 63,654 | ||||||
Other intangibles, net
|
15,547 | 16,731 | ||||||
Deferred financing costs, net
|
2,667 | 3,078 | ||||||
Long-term investments
|
10,311 | 10,299 | ||||||
Deferred taxes, non-current
|
1,013 | 930 | ||||||
Other
|
2,927 | 3,328 | ||||||
TOTAL OTHER LONG-TERM ASSETS
|
124,172 | 130,179 | ||||||
TOTAL ASSETS
|
$ | 390,248 | $ | 369,565 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY:
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Trade accounts payable
|
$ | 21,393 | $ | 21,784 | ||||
Accrued compensation
|
4,473 | 7,533 | ||||||
Accrued royalties
|
5,561 | 5,768 | ||||||
Accrued administration fees
|
2,307 | 2,204 | ||||||
Income taxes payable
|
594 | 910 | ||||||
Accrued expenses and other liabilities
|
4,823 | 5,092 | ||||||
TOTAL CURRENT LIABILITIES
|
39,151 | 43,291 | ||||||
LONG-TERM LIABILITIES:
|
||||||||
Long-term debt
|
106,656 | 104,637 | ||||||
Purchase consideration payable
|
16,038 | 16,113 | ||||||
Deferred taxes – non-current
|
825 | 1,991 | ||||||
Product warranty liability
|
— | 1,299 | ||||||
Lease incentive obligation and other long-term liabilities
|
1,386 | 1,153 | ||||||
TOTAL LONG-TERM LIABILITIES
|
124,905 | 125,193 | ||||||
TOTAL LIABILITIES
|
164,056 | 168,484 | ||||||
SHAREHOLDERS’ EQUITY:
|
||||||||
Common stock, no par value – 150,000,000 shares authorized;
96,191,057 and 95,844,012 shares issued and outstanding at
June 30, 2013 and December 31, 2012, respectively
|
232,288 | 226,035 | ||||||
Warrants to acquire common stock
|
17,946 | 17,946 | ||||||
Accumulated deficit
|
(13,517 | ) | (36,996 | ) | ||||
Accumulated other comprehensive loss
|
(10,525 | ) | (5,904 | ) | ||||
TOTAL SHAREHOLDERS’ EQUITY
|
226,192 | 201,081 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
|
$ | 390,248 | $ | 369,565 |
THREE MONTHS ENDED
JUNE 30,
|
SIX MONTHS ENDED
JUNE 30,
|
||||||||||||||||
2013
|
2012
|
2013
|
2012
|
||||||||||||||
Revenues
|
$ | 77,012 | $ | 63,287 | $ | 150,866 | $ | 115,004 | |||||||||
Cost of sales (exclusive of amortization of intangibles
included below)
|
34,920 | 27,560 | 69,629 | 48,376 | |||||||||||||
GROSS PROFIT
|
42,092 | 35,727 | 81,237 | 66,628 | |||||||||||||
Selling, general and administrative expenses
|
13,113 | 10,940 | 25,448 | 21,279 | |||||||||||||
Acquisition-related costs
|
— | 184 | 519 | 8,644 | |||||||||||||
Research and development expenses
|
5,051 | 4,073 | 11,020 | 6,950 | |||||||||||||
Amortization of intangibles
|
1,677 | 1,754 | 3,410 | 3,317 | |||||||||||||
TOTAL OPERATING EXPENSES
|
19,841 | 16,951 | 40,397 | 40,190 | |||||||||||||
OPERATING INCOME
|
22,251 | 18,776 | 40,840 | 26,438 | |||||||||||||
Amortization of deferred financing costs
|
(207 | ) | (195 | ) | (411 | ) | (388 | ) | |||||||||
Interest expense, net
|
(2,028 | ) | (2,210 | ) | (4,232 | ) | (4,437 | ) | |||||||||
Other (expense) income, net
|
(34 | ) | — | 42 | — | ||||||||||||
INCOME BEFORE INCOME TAXES
|
19,982 | 16,371 | 36,239 | 21,613 | |||||||||||||
Income tax provision
|
7,345 | 6,665 | 12,760 | 8,799 | |||||||||||||
CONSOLIDATED NET INCOME
|
$ | 12,637 | $ | 9,706 | $ | 23,479 | $ | 12,814 | |||||||||
CONSOLIDATED NET INCOME PER SHARE:
|
|||||||||||||||||
BASIC
|
$ | 0.13 | $ | 0.10 | $ | 0.24 | $ | 0.13 | |||||||||
DILUTED
|
$ | 0.11 | $ | 0.09 | $ | 0.21 | $ | 0.12 | |||||||||
SHARES USED IN COMPUTING CONSOLIDATED
NET INCOME PER SHARE:
|
|||||||||||||||||
BASIC
|
96,122 | 95,096 | 96,025 | 95,054 | |||||||||||||
DILUTED
|
112,328 | 110,513 | 112,010 | 109,879 | |||||||||||||
COMPREHENSIVE INCOME:
|
|||||||||||||||||
Consolidated net income
|
$ | 12,637 | $ | 9,706 | $ | 23,479 | $ | 12,814 | |||||||||
Foreign currency translation loss
|
(4,979 | ) | (4,757 | ) | (4,621 | ) | (6,960 | ) | |||||||||
COMPREHENSIVE INCOME
|
$ | 7,658 | $ | 4,949 | $ | 18,858 | $ | 5,854 |
Warrants
|
||||||||||||||||||||||||
to acquire
|
Other
|
|||||||||||||||||||||||
Common
|
Accumulated
|
Comprehensive
|
||||||||||||||||||||||
Shares
|
Amount
|
Stock
|
Deficit
|
Loss
|
Total
|
|||||||||||||||||||
BALANCES AT DECEMBER 31, 2012
|
95,844 | $ | 226,035 | $ | 17,946 | $ | (36,996 | ) | $ | (5,904 | ) | $ | 201,081 | |||||||||||
Consolidated net income
|
— | — | — | 23,479 | — | 23,479 | ||||||||||||||||||
Exercise of stock options
|
270 | 676 | — | — | — | 676 | ||||||||||||||||||
Employee stock purchase plan issuances
|
61 | 588 | — | — | — | 588 | ||||||||||||||||||
Compensation and share issuances
related to restricted stock awards
|
16 | 414 | — | — | — | 414 | ||||||||||||||||||
Stock-based compensation expense
|
— | 3,830 | — | — | — | 3,830 | ||||||||||||||||||
Foreign currency translation adjustment
|
— | — | — | — | (4,621 | ) | (4,621 | ) | ||||||||||||||||
Excess tax benefit – stock compensation
|
— | 745 | — | — | — | 745 | ||||||||||||||||||
BALANCES AT JUNE 30, 2013
|
96,191 | $ | 232,288 | $ | 17,946 | $ | (13,517 | ) | $ | (10,525 | ) | $ | 226,192 |
SIX MONTHS ENDED
JUNE 30,
|
||||||||
2013
|
2012
|
|||||||
OPERATING ACTIVITIES:
|
||||||||
Consolidated net income
|
$ | 23,479 | $ | 12,814 | ||||
Adjustments to reconcile consolidated net income to net cash provided by
operating activities:
|
||||||||
Depreciation and amortization
|
6,651 | 5,319 | ||||||
Write-off and amortization of deferred financing fees
|
411 | 388 | ||||||
Amortization of unfavorable contract liability
|
(318 | ) | — | |||||
Non-cash stock compensation expense
|
4,244 | 3,181 | ||||||
Non-cash interest expense
|
2,263 | 2,387 | ||||||
Deferred income taxes
|
1,201 | 3,261 | ||||||
Excess tax benefit from stock compensation
|
(745 | ) | (1,595 | ) | ||||
Non-cash settlement of product warranty liability
|
(1,299 | ) | — | |||||
Equity in earnings of unconsolidated joint venture
|
(76 | ) | — | |||||
Changes in operating assets and liabilities:
|
||||||||
Trade accounts receivable
|
(6,908 | ) | (9,980 | ) | ||||
Inventories
|
(4,428 | ) | (9,561 | ) | ||||
Prepaid expenses and other current assets
|
538 | (1,071 | ) | |||||
Trade accounts payable
|
(151 | ) | (2,014 | ) | ||||
Accrued expenses and other liabilities
|
(3,464 | ) | 3,157 | |||||
NET CASH PROVIDED BY OPERATING ACTIVITIES
|
21,398 | 6,286 | ||||||
INVESTING ACTIVITIES:
|
||||||||
Payments for acquisitions
|
(513 | ) | (55,224 | ) | ||||
Purchases of property, plant and equipment
|
(5,159 | ) | (12,253 | ) | ||||
NET CASH USED IN INVESTING ACTIVITIES
|
(5,672 | ) | (67,477 | ) | ||||
FINANCING ACTIVITIES:
|
||||||||
Excess tax benefit from stock compensation
|
745 | 1,595 | ||||||
Proceeds under stock option and stock purchase plans
|
1,265 | 523 | ||||||
NET CASH PROVIDED BY FINANCING ACTIVITIES
|
2,010 | 2,118 | ||||||
Effect of exchange rate changes on cash and cash equivalents
|
(105 | ) | (479 | ) | ||||
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
17,631 | (59,552 | ) | |||||
Cash and cash equivalents at beginning of period
|
40,781 | 83,962 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD
|
$ | 58,412 | $ | 24,410 | ||||
SUPPLEMENTAL DISCLOSURES:
|
||||||||
Amount paid for interest
|
$ | 2,152 | $ | 2,141 | ||||
Amount paid for income taxes
|
$ | 11,936 | $ | 5,819 |
|
-
|
Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. The carrying value of the Company’s cash and cash equivalents are considered Level 1 assets.
|
|
-
|
Level 2—Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. The Company does not have any Level 2 assets or liabilities.
|
|
-
|
Level 3—Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The purchase consideration payable related to the Company’s acquisition on December 22, 2011 of three branded, injectable drug products from the U.S. subsidiary of H. Lundbeck A/S (the “Lundbeck Acquisition”) is a Level 3 liability.
|
Fair Value Measurements at Reporting Date, Using:
|
||||||||||||||||
Quoted Prices
|
Significant
|
|||||||||||||||
in Active
|
Other
|
Significant
|
||||||||||||||
Markets for
|
Observable
|
Unobservable
|
||||||||||||||
June 30,
|
Identical Items
|
Inputs
|
Inputs
|
|||||||||||||
Description
|
2013
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
||||||||||||
Cash and cash equivalents
|
$ | 58,412 | $ | 58,412 | $ | — | $ | — | ||||||||
Total assets
|
$ | 58,412 | $ | 58,412 | $ | — | $ | — | ||||||||
Purchase consideration payable
|
$ | 14,451 | $ | — | $ | — | $ | 14,451 | ||||||||
Total liabilities
|
$ | 14,451 | $ | — | $ | — | $ | 14,451 |
Quoted Prices
|
Significant
|
|||||||||||||||
in Active
|
Other
|
Significant
|
||||||||||||||
Markets for
|
Observable
|
Unobservable
|
||||||||||||||
December 31,
|
Identical Items
|
Inputs
|
Inputs
|
|||||||||||||
Description
|
2012
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
||||||||||||
Cash and cash equivalents
|
$ | 40,781 | $ | 40,781 | $ | — | $ | — | ||||||||
Total assets
|
$ | 40,781 | $ | 40,781 | $ | — | $ | — | ||||||||
Purchase consideration payable
|
$ | 14,208 | $ | — | $ | — | $ | 14,208 | ||||||||
Total liabilities
|
$ | 14,208 | $ | — | $ | — | $ | 14,208 |
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||
Expected volatility
|
58% | 84% | 59% | 85% | ||||||||
Expected life (in years)
|
4.0 | 4.0 | 4.0 | 4.0 | ||||||||
Risk-free interest rate
|
0.73% | 0.77% | 0.74% | 0.81% | ||||||||
Dividend yield
|
—% | —% | —% | —% | ||||||||
Fair value per stock option
|
$6.81 | $7.80 | $6.77 | $7.84 | ||||||||
Forfeiture rate
|
8% | 8% | 8% | 8% |
Number of
Options
(in thousands)
|
Weighted
Average
Exercise Price
|
Weighted
Average
Remaining Contractual
Term (Years)
|
Aggregate
Intrinsic Value
|
|||||||||||||
Outstanding at December 31, 2012
|
9,727
|
$
|
4.22
|
2.55
|
$
|
88,918,000
|
||||||||||
Granted
|
276
|
15.02
|
||||||||||||||
Exercised
|
(270
|
)
|
2.51
|
|||||||||||||
Forfeited
|
(11
|
)
|
10.81
|
|||||||||||||
Outstanding at June 30, 2013
|
9,722
|
$
|
4.57
|
2.15
|
$
|
87,484,000
|
||||||||||
Exercisable at June 30, 2013
|
7,634
|
$
|
2.85
|
1.72
|
$
|
81,491,000
|
Number
|
Weighted Average
|
|||||||
of Shares
|
Grant Date Fair Value
|
|||||||
Non-vested at December 31, 2012
|
17,500
|
$
|
14.63
|
|||||
Granted
|
31,899
|
$
|
15.36
|
|||||
Forfeited
|
—
|
—
|
||||||
Vested
|
(15,946
|
)
|
$
|
15.36
|
||||
Non-vested at June 30, 2013
|
33,453
|
$
|
14.98
|
JUNE 30,
|
DECEMBER 31,
|
|||||||
2013
|
2012
|
|||||||
Gross accounts receivable
|
$
|
79,696
|
$
|
74,855
|
||||
Less reserves for:
|
||||||||
Chargebacks and rebates
|
(11,515
|
)
|
(13,452
|
)
|
||||
Product returns
|
(8,359
|
)
|
(8,409
|
)
|
||||
Discounts and allowances
|
(1,616
|
)
|
(1,362
|
)
|
||||
Advertising and promotions
|
(468
|
)
|
(585
|
)
|
||||
Doubtful accounts
|
(31
|
)
|
(30
|
)
|
||||
Trade accounts receivable, net
|
$
|
57,707
|
$
|
51,017
|
JUNE 30,
|
DECEMBER 31,
|
|||||||
2013
|
2012
|
|||||||
Finished goods
|
$
|
25,004
|
$
|
24,657
|
||||
Work in process
|
3,081
|
3,743
|
||||||
Raw materials and supplies
|
28,618
|
24,095
|
||||||
Inventories, net
|
$
|
56,703
|
$
|
52,495
|
JUNE 30,
|
DECEMBER 31,
|
|||||||
2013
|
2012
|
|||||||
Land
|
$
|
2,573
|
$
|
2,715
|
||||
Buildings and leasehold improvements
|
44,388
|
43,190
|
||||||
Furniture and equipment
|
74,740
|
70,874
|
||||||
Sub-total
|
121,701
|
116,779
|
||||||
Accumulated depreciation
|
(50,757
|
)
|
(47,635
|
)
|
||||
Property, plant and equipment placed in service, net
|
70,944
|
69,144
|
||||||
Construction in progress
|
10,089
|
11,535
|
||||||
Property, plant and equipment, net
|
$
|
81,033
|
$
|
80,679
|
Ophthalmic
|
Contract Services
|
Total
|
||||||||||
December 31, 2012
|
$ | 11,863 | $ | 20,296 | $ | 32,159 | ||||||
Currency translation adjustments
|
─
|
(1,672 | ) | (1,672 | ) | |||||||
June 30, 2013
|
$ | 11,863 | $ | 18,624 | $ | 30,487 |
Gross
Amount
|
Accumulated
Amortization
|
Net
Balance
|
Wgtd Avg Remaining
Amortization Period
|
|||||||||||||
JUNE 30, 2013
|
||||||||||||||||
Goodwill
|
$ | 30,487 |
$ ─
|
$ | 30,487 | N/A | ||||||||||
Product licensing rights
|
93,634 | (32,414 | ) | 61,220 |
13.4 years
|
|||||||||||
Trademarks
|
9,500 | (686 | ) | 8,814 |
27.8 years
|
|||||||||||
Customer relationships
|
6,249 | (1,192 | ) | 5,057 |
9.7 years
|
|||||||||||
Non-compete agreement
|
2,517 | (841 | ) | 1,676 |
2.7 years
|
|||||||||||
$ | 142,387 | $ | (35,133 | ) | $ | 107,254 | ||||||||||
DECEMBER 31, 2012
|
||||||||||||||||
Goodwill
|
$ | 32,159 |
$ ─
|
$ | 32,159 | N/A | ||||||||||
Product licensing rights
|
93,534 | (29,880 | ) | 63,654 |
13.8 years
|
|||||||||||
Trademarks
|
9,500 | (528 | ) | 8,972 |
28.3 years
|
|||||||||||
Customer relationships
|
6,460 | (865 | ) | 5,595 |
9.8 years
|
|||||||||||
Non-compete agreement
|
2,743 | (579 | ) | 2,164 |
3.2 years
|
|||||||||||
$ | 144,396 | $ | (31,852 | ) | $ | 112,544 |
JUNE 30,
|
DECEMBER 31,
|
|||||||
2013
|
2012
|
|||||||
Carrying amount of equity component
|
$ | 20,470 | $ | 20,470 | ||||
Carrying amount of the liability component
|
106,656 | 104,637 | ||||||
Unamortized discount of the liability component
|
13,344 | 15,363 | ||||||
Unamortized deferred financing costs
|
2,413 | 2,778 |
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
Expense Description
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
Interest expense at 3.5% coupon rate (1)
|
$ | 1,050 | $ | 1,050 | $ | 2,100 | $ | 2,100 | ||||||||
Debt discount amortization (1)
|
1,019 | 948 | 2,020 | 1,880 | ||||||||||||
Amortization of deferred financing costs
|
184 | 172 | 365 | 340 | ||||||||||||
$ | 2,253 | $ | 2,170 | $ | 4,485 | $ | 4,320 |
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||||||
Consolidated net income
|
$ | 12,637 | $ | 9,706 | $ | 23,479 | $ | 12,814 | ||||||||
Consolidated net income per share:
|
||||||||||||||||
Basic
|
$ | 0.13 | $ | 0.10 | $ | 0.24 | $ | 0.13 | ||||||||
Diluted
|
$ | 0.11 | $ | 0.09 | $ | 0.21 | $ | 0.12 | ||||||||
|
||||||||||||||||
Shares used in computing consolidated net income per
share:
|
||||||||||||||||
Weighted average basic shares outstanding
|
96,122 | 95,096 | 96,025 | 95,054 | ||||||||||||
Dilutive securities:
|
||||||||||||||||
Stock option and unvested RSAs
|
4,380 | 4,294 | 4,383 | 4,202 | ||||||||||||
Stock warrants
|
6,614 | 6,569 | 6,564 | 6,537 | ||||||||||||
Shares issuable upon conversion of convertible notes (1)
|
5,212 | 4,554 | 5,038 | 4,086 | ||||||||||||
Total dilutive securities
|
16,206 | 15,417 | 15,985 | 14,825 | ||||||||||||
Weighted average diluted shares outstanding
|
112,328 | 110,513 | 112,010 | 109,879 | ||||||||||||
Shares subject to stock options omitted from the calculation
of net income per share as their effect would have been
anti-dilutive
|
1,373 | 345 | 1,289 | 224 |
(1)
|
Shares issuable upon conversion of convertible notes is based on the assumption that the Company would repay the principal of the notes in cash and pay any incremental value in shares of common stock.
|
|
-
|
Ophthalmic
|
|
-
|
Hospital Drugs & Injectables
|
|
-
|
Contract Services
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||||||
Revenues:
|
||||||||||||||||
Hospital Drugs & Injectables
|
$ | 42,599 | $ | 30,284 | $ | 83,033 | $ | 57,660 | ||||||||
Ophthalmic
|
28,490 | 25,150 | 54,195 | 46,961 | ||||||||||||
Contract Services
|
5,923 | 7,853 | 13,638 | 10,383 | ||||||||||||
Total revenues
|
$ | 77,012 | $ | 63,287 | $ | 150,866 | $ | 115,004 | ||||||||
Gross Profit:
|
||||||||||||||||
Hospital Drugs & Injectables
|
25,096 | $ | 18,813 | $ | 47,910 | $ | 35,854 | |||||||||
Ophthalmic
|
15,545 | 14,513 | 30,261 | 27,232 | ||||||||||||
Contract Services
|
1,451 | 2,401 | 3,066 | 3,542 | ||||||||||||
Total gross profit
|
42,092 | 35,727 | 81,237 | 66,628 | ||||||||||||
Operating expenses
|
19,841 | 16,951 | 40,397 | 40,190 | ||||||||||||
Operating income
|
22,251 | 18,776 | 40,840 | 26,438 | ||||||||||||
Other (expense) income, net
|
(2,269 | ) | (2,405 | ) | (4,601 | ) | (4,825 | ) | ||||||||
Income before income taxes
|
$ | 19,982 | $ | 16,371 | $ | 36,239 | $ | 21,613 |
Consideration:
|
Adjusted Fair
Valuation
|
|||
Cash paid
|
$ | 55,224 | ||
Less working capital shortfall refunded by sellers
|
(1,028 | ) | ||
$ | 54,196 | |||
Acquisition-related costs:
|
||||
Stamp duties paid for transfer of land and buildings
|
$ | 1,583 | ||
Acquisition-related compensation expense
|
7,771 | |||
Due diligence, legal, travel and other acquisition-related costs
|
676 | |||
$ | 10,030 | |||
Recognized amounts of identifiable assets acquired and liabilities assumed:
|
||||
Accounts receivable
|
$ | 2,130 | ||
Inventory
|
1,799 | |||
Land
|
2,583 | |||
Buildings, plant and equipment
|
8,474 | |||
Construction in progress
|
14,231 | |||
Goodwill, deductible
|
22,613 | |||
Other intangible assets, deductible
|
5,908 | |||
Other assets
|
38 | |||
Assumed liabilities
|
(2,878 | ) | ||
Deferred tax liabilities
|
(702 | ) | ||
$ | 54,196 |
Six months ended
June 30, 2012
|
||||
Revenue
|
$ | 119,008 | ||
Net income
|
$ | 13,158 | ||
Net income per diluted share
|
$ | 0.12 |
Year of Payment
|
Amount
|
|||
2013
|
$
|
3,664
|
||
2014
|
599
|
|||
2015
|
198
|
|||
2016
|
200
|
|||
Total
|
$
|
4,661
|
Three months ended June 30,
|
Six months ended June 30,
|
|||||||||||||||
Big 3 Wholesalers combined:
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
Percentage of gross sales
|
57 | % | 55 | % | 58 | % | 53 | % | ||||||||
Percentage of net sales revenues
|
38 | % | 41 | % | 40 | % | 37 | % | ||||||||
June 30,
2013
|
December 31,
2012
|
|||||||||||||||
Percentage of gross trade accounts receivable
|
59 | % | 67 | % |
Three Months ended
June 30,
|
Six Months ended
June 30,
|
|||||||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||||||
Income before income taxes
|
$ | 19,982 | $ | 16,371 | $ | 36,239 | $ | 21,613 | ||||||||
Income tax provision
|
7,345 | 6,665 | 12,760 | 8,799 | ||||||||||||
Net income
|
$ | 12,637 | $ | 9,706 | $ | 23,479 | $ | 12,814 | ||||||||
Income tax provision as a percentage of income before income taxes
|
36.8 | % | 40.7 | % | 35.2 | % | 40.7 | % |
CONDENSED STATEMENTS OF INCOME
|
|||||||||||||||
Three months ended
|
Six months ended
|
||||||||||||||
June 30,
|
June 30,
|
||||||||||||||
2013
|
2012
|
2013
|
2012
|
||||||||||||
Revenues
|
$ | 1 | $ | — | $ | 156 | $ | — | |||||||
Cost of sales
|
(1 | ) | — | (1 | ) | — | |||||||||
Gross profit
|
2 | — | 157 | — | |||||||||||
Operating expenses
|
— | — | 2 | — | |||||||||||
Operating income
|
2 | — | 155 | — | |||||||||||
Income tax provision
|
— | — | — | — | |||||||||||
Net income
|
$ | 2 | $ | — | $ | 155 | $ | — |
CONDENSED BALANCE SHEETS
|
||||||||
June 30,
|
December 31,
|
|||||||
2013
|
2012
|
|||||||
Assets:
|
||||||||
Cash
|
$ | 596 | $ | 794 | ||||
Total assets
|
$ | 596 | $ | 794 | ||||
Liabilities and members’ equity:
|
||||||||
Trade accounts payable and other accrued
liabilities
|
$ | 20 | $ | 308 | ||||
Accounts payable – members
|
59 | 123 | ||||||
Total liabilities
|
79 | 431 | ||||||
Members’ equity, net of advances
|
517 | 363 | ||||||
Total liabilities and members’ equity
|
$ | 596 | $ | 794 |
●
|
Our ability to comply with all of the requirements of the U.S. Food and Drug Administration (“FDA”), including current Good Manufacturing Practices regulations;
|
||
●
|
Our ability to obtain additional funding or financing to operate and grow our business;
|
||
●
|
The effects of federal, state and other governmental regulation on our business;
|
||
●
|
Our ability to obtain and maintain regulatory approvals for our products;
|
||
●
|
Our success in developing, manufacturing, acquiring and marketing new products;
|
||
●
|
Our ability to generate cash flow from operations sufficient to meet our working capital requirements;
|
||
●
|
The success of our strategic partnerships for the development and marketing of new products;
|
||
●
|
Our ability to bring new products to market and the effects of sales of such products on our financial results;
|
||
●
|
Our ability to successfully integrate acquired businesses and products;
|
||
●
|
The effects of competition from generic pharmaceuticals and from other pharmaceutical companies;
|
||
●
|
Availability of raw materials needed to produce our products; and
|
||
●
|
Other factors referred to in this Form 10-Q, our Form 10-K and our other SEC filings.
|
Three months ended June 30,
|
Six months ended June 30,
|
|||||||||||||||||||||||||||||||
2013
|
2012
|
2013
|
2012
|
|||||||||||||||||||||||||||||
Amount
|
% of
Revenue
|
Amount
|
% of
Revenue
|
Amount
|
% of
Revenue
|
Amount
|
% of
Revenue
|
|||||||||||||||||||||||||
Revenues:
|
||||||||||||||||||||||||||||||||
Hospital drugs & injectables
|
$ | 42,599 | 55.3 | % | $ | 30,284 | 47.9 | % | $ | 83,033 | 55.0 | % | $ | 57,660 | 50.1 | % | ||||||||||||||||
Ophthalmic
|
28,490 | 37.0 | % | 25,150 | 39.7 | % | 54,195 | 35.9 | % | 46,961 | 40.8 | % | ||||||||||||||||||||
Contract services
|
5,923 | 7.7 | % | 7,853 | 12.4 | % | 13,638 | 9.1 | % | 10,383 | 9.0 | % | ||||||||||||||||||||
Total revenues
|
77,012 | 100.0 | % | 63,287 | 100.0 | % | 150,866 | 100.0 | % | 115,004 | 100.0 | % | ||||||||||||||||||||
Gross profit:
|
||||||||||||||||||||||||||||||||
Hospital drugs & injectables
|
25,096 | 58.9 | % | 18,813 | 62.1 | % | 47,910 | 57.7 | % | 35,854 | 62.2 | % | ||||||||||||||||||||
Ophthalmic
|
15,545 | 54.6 | % | 14,513 | 57.7 | % | 30,261 | 55.8 | % | 27,232 | 58.0 | % | ||||||||||||||||||||
Contract services
|
1,451 | 24.5 | % | 2,401 | 30.6 | % | 3,066 | 22.5 | % | 3,542 | 34.1 | % | ||||||||||||||||||||
Total gross profit
|
42,092 | 54.7 | % | 35,727 | 56.5 | % | 81,237 | 53.8 | % | 66,628 | 57.9 | % | ||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||||||||||
SG&A expenses
|
13,113 | 17.0 | % | 10,940 | 17.3 | % | 25,448 | 16.9 | % | 21,279 | 18.5 | % | ||||||||||||||||||||
Acquisition-related costs
|
─
|
─
|
% | 184 | 0.3 | % | 519 | 0.3 | % | 8,644 | 7.5 | % | ||||||||||||||||||||
R&D expenses
|
5,051 | 6.6 | % | 4,073 | 6.4 | % | 11,020 | 7.3 | % | 6,950 | 6.0 | % | ||||||||||||||||||||
Amortization & write-down of
intangible assets
|
1,677 | 2.2 | % | 1,754 | 2.8 | % | 3,410 | 2.3 | % | 3,317 | 2.9 | % | ||||||||||||||||||||
Operating income
|
$ | 22,251 | 28.9 | % | $ | 18,776 | 29.7 | % | $ | 40,840 | 27.1 | % | $ | 26,438 | 23.0 | % | ||||||||||||||||
Other (expense) income, net
|
(2,269 | ) | (3.0 | %) | (2,405 | ) | (3.8 | %) | (4,601 | ) | (3.1 | %) | (4,825 | ) | (4.2 | %) | ||||||||||||||||
Income before income taxes
|
19,982 | 25.9 | % | 16,371 | 25.9 | % | 36,239 | 24.0 | % | 21,613 | 18.8 | % | ||||||||||||||||||||
Income tax provision
|
7,345 | 9.5 | % | 6,665 | 10.6 | % | 12,760 | 8.4 | % | 8,799 | 7.7 | % | ||||||||||||||||||||
Net income (loss)
|
$ | 12,637 | 16.4 | % | $ | 9,706 | 15.3 | % | $ | 23,479 | 15.6 | % | $ | 12,814 | 11.1 | % |
AKORN, INC.
|
||
/s/ TIMOTHY A. DICK
|
||
Timothy A. Dick
|
||
Chief Financial Officer
|
||
(on behalf of the registrant and as its
Principal Financial Officer)
|
Exhibit
|
||
No.
|
Description
|
|
31.1 *
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
|
|
31.2 *
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
|
|
32.1 *
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. § 1350.
|
|
32.2 *
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. § 1350.
|
|
101
|
The financial statements and footnotes from the Akorn, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, filed on August 9, 2013, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Statement of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
|
/s/ RAJAT RAI
|
||||
Rajat Rai
|
||||
Chief Executive Officer
|
/s/ TIMOTHY A. DICK
|
||||
Timothy A. Dick
|
||||
Chief Financial Officer
|
/s/ RAJAT RAI
|
||||
Rajat Rai
|
||||
Chief Executive Officer
|
/s/ TIMOTHY A. DICK
|
||||
Timothy A. Dick
|
||||
Chief Financial Officer
|
INDUSTRY SEGMENT INFORMATION
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INDUSTRY SEGMENT INFORMATION [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INDUSTRY SEGMENT INFORMATION | NOTE 11 — INDUSTRY SEGMENT INFORMATION During the three and six month periods ended June 30, 2013 and June 30, 2012, the Company reported results for three segments:
The ophthalmic segment manufactures, markets and distributes diagnostic and therapeutic pharmaceuticals, as well as a line of branded OTC dry eye treatment products and a portfolio of private label OTC opthalmic products. The hospital drugs & injectables segment manufactures, markets and distributes drugs and injectable pharmaceuticals, primarily in niche markets, as well as certain vaccines. The contract services segment manufactures products for third party pharmaceutical and biotechnology customers based on their specifications. The contract services segment also includes the operating results of the Company's subsidiary in India – Akorn India Private Limited ("AIPL") – as its principal current business activity involves the manufacture of drugs on contract for other drug companies. The Financial information about th Company's reportable segments is based upon internal financial reports that aggregate certain operating information. The Company's chief operating decision maker, as defined in ASC Topic 280, Segment Reporting, is its chief executive officer ("CEO"). The Company's CEO oversees operational assessments and resource allocations based upon the results of the Company's reportable segments, all of which have available discrete financial information. Selected financial information by industry segment is presented below (in thousands).
The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Inter-segment activity at the gross profit level has been minimal. The Company does not identify total assets by segment for internal purposes, as certain of the Company's manufacturing and warehouse facilities support more than one segment. |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract] | ||||
Revenues | $ 77,012 | $ 63,287 | $ 150,866 | $ 115,004 |
Cost of sales (exclusive of amortization of intangibles included below) | 34,920 | 27,560 | 69,629 | 48,376 |
GROSS PROFIT | 42,092 | 35,727 | 81,237 | 66,628 |
Selling, general and administrative expenses | 13,113 | 10,940 | 25,448 | 21,279 |
Acquisition-related costs | 0 | 184 | 519 | 8,644 |
Research and development expenses | 5,051 | 4,073 | 11,020 | 6,950 |
Amortization of intangibles | 1,677 | 1,754 | 3,410 | 3,317 |
TOTAL OPERATING EXPENSES | 19,841 | 16,951 | 40,397 | 40,190 |
OPERATING INCOME | 22,251 | 18,776 | 40,840 | 26,438 |
Amortization of deferred financing costs | (207) | (195) | (411) | (388) |
Interest expense, net | (2,028) | (2,210) | (4,232) | (4,437) |
Other (expense) income, net | (34) | 0 | 42 | 0 |
INCOME BEFORE INCOME TAXES | 19,982 | 16,371 | 36,239 | 21,613 |
Income tax provision | 7,345 | 6,665 | 12,760 | 8,799 |
CONSOLIDATED NET INCOME | 12,637 | 9,706 | 23,479 | 12,814 |
CONSOLIDATED NET INCOME PER SHARE: | ||||
BASIC (in dollars per share) | $ 0.13 | $ 0.10 | $ 0.24 | $ 0.13 |
DILUTED (in dollars per share) | $ 0.11 | $ 0.09 | $ 0.21 | $ 0.12 |
SHARES USED IN COMPUTING CONSOLIDATED NET INCOME PER SHARE: | ||||
BASIC (in shares) | 96,122 | 95,096 | 96,025 | 95,054 |
DILUTED (in shares) | 112,328 | 110,513 | 112,010 | 109,879 |
COMPREHENSIVE INCOME: | ||||
CONSOLIDATED NET INCOME | 12,637 | 9,706 | 23,479 | 12,814 |
Foreign currency translation loss | (4,979) | (4,757) | (4,621) | (6,960) |
COMPREHENSIVE INCOME | $ 7,658 | $ 4,949 | $ 18,858 | $ 5,854 |
REVENUE RECOGNITION
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
REVENUE RECOGNITION [Abstract] | |
REVENUE RECOGNITION | NOTE 4 — REVENUE RECOGNITION Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the sales price is fixed or determinable, and collectability is reasonably assured. Revenue from product sales is recognized when title and risk of loss have passed to the customer. Provision for estimated chargebacks, rebates, discounts, product returns and doubtful accounts is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
|
6 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |||||||
Consolidation | Consolidation: The accompanying condensed consolidated financial statements include the accounts of Akorn, Inc. and its wholly-owned domestic and foreign subsidiaries. All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of Akorn India Private Limited ("AIPL") have been translated from Indian rupees to U.S. dollars based on the currency translation rates in effect during the period presented or as of the date of consolidation, as applicable. |
||||||
Use of Estimates | Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. |
||||||
Chargebacks and Rebates | Chargebacks and Rebates: The Company enters into contractual agreements with certain third parties such as hospitals and group-purchasing organizations to sell certain products at predetermined prices. The parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product. The Company reduces gross sales and increases the chargeback allowance by the estimated chargeback amount for each product sold to a wholesaler. The Company reduces the chargeback allowance when it processes a request for a chargeback from a wholesaler. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company's provision for chargebacks is fully reserved for at the time when sales revenues are recognized. Management obtains certain wholesaler inventory reports to aid in analyzing the reasonableness of the chargeback allowance. The Company assesses the reasonableness of its chargeback allowance by applying the product chargeback percentage based on historical activity to the quantities of inventory on hand per the wholesaler inventory reports and an estimate of in-transit inventory that is not reported on the wholesaler inventory reports at the end of the period. In accordance with its accounting policy, the Company estimates the percentage amount of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a six-quarter trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends or other information indicates that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change. The Company used an estimate of 90.0% during the quarter and six months ended June 30, 2013 and 98.5% during the quarter and six months ended June 30, 2012. |
||||||
Sales Returns | Sales Returns: Certain of the Company's products are sold with the customer having the right to return the product within specified periods and guidelines for a variety of reasons, including but not limited to, pending expiration dates. Provisions are made at the time of sale based upon tracked historical experience, by customer in some cases. One-time historical factors or pending new developments that would impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the balance required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the wholesaler's inventory information to assess the magnitude of unconsumed product that may result in a sales return to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the end-user pull through for sales of the Company's products and ultimately impact the level of sales returns. Actual returns experience and trends are factored into the Company's estimates each quarter as market conditions change. Actual returns processed can vary materially from period to period. |
||||||
Allowance for Coupons and Promotions | Allowance for Coupons and Promotions: The Company issues coupons from time to time redeemable against our TheraTears® eye care products. Upon release of coupons into the market, the Company records an estimate of the dollar value of coupons expected to be redeemed. This estimate is based on historical experience and is adjusted as needed based on actual redemptions. In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales of its products. Upon receiving confirmation that a promotion was run, the Company accrues an estimate of the dollar amount expected to be owed back to the retailer. This estimate is trued up upon receipt of invoice from the retailer. |
||||||
Advertising and Promotional Allowances to Customers | For our treatment of advertising and promotional expenses paid to customers, we referred to guidance contained within ASC 605-50, Customer Payments and Incentives. |
||||||
Inventories | Inventories: Inventories are stated at the lower of cost (average cost method) or market (see Note 4 — "Inventories"). The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory with a carrying value in excess of its net realizable value ("NRV"). For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow moving based upon recent sales activity by unit and wholesaler inventory information. The Company also analyzes its raw material and component inventory for slow moving items. The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval. The Company considers the shelf life of the product in relation to the product timeline for approval. |
||||||
Income taxes | Income taxes: Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. |
||||||
Fair Value of Financial Instruments | Fair Value of Financial Instruments: The Company applies ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC Topic 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company's principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC Topic 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions based on market data and the entity's judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances. The valuation hierarchy is composed of three categories. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described below:
|
||||||
Business Combinations | Business Combinations: Business combinations are accounted for under ASC 805, Business Combinations, using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill will be determined as the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Under the acquisition method of accounting, the Company will identify the acquirer and the closing date and apply applicable recognition principles and conditions. Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred and the services are received. |
BUSINESS COMBINATIONS
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BUSINESS COMBINATIONS [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BUSINESS COMBINATIONS | NOTE 12 — BUSINESS COMBINATIONS On February 28, 2012, Akorn India Private Limited ("AIPL"), a wholly owned subsidiary of the Company completed the acquisition of selected assets of Kilitch Drugs (India) Limited ("KDIL"). This acquisition (the "Kilitch Acquisition") was pursuant to the terms of the Business Transfer Agreement (the "BTA") entered into among the Company, KDIL and the members of the promoter group of KDIL on October 5, 2011. In accordance with terms contained in the BTA, the Company also closed on a related Product Transfer Agreement between the Company and NBZ Pharma Limited ("NBZ"), a company associated with KDIL. The primary assets acquired were KDIL's manufacturing plant in Paonta Sahib, Himachal Pradesh, India, and its existing book of business. KDIL was engaged in the manufacture and sale of pharmaceutical products for contract customers in India and for export to various unregulated world markets. While the Paonta Sahib manufacturing facility is not currently certified by the U.S. Food and Drug Administration (the "FDA") for the exporting of drugs to the U.S., the facility was designed with future FDA certification in mind. Accordingly, the Kilitch Acquisition provided the Company with the potential for future expansion of its manufacturing capacity for products to be sold in the U.S., as well as the opportunity to expand the Company's footprint into markets outside the U.S. The Company has determined that the assets acquired through the Kilitch Acquisition constitute a "business" as defined by Rule 11-01(d) of Regulation S-X and ASC 805, Business Combinations. Accordingly, the Company has accounted for the Kilitch Acquisition as a business combination. Total purchase consideration was approximately $55.2 million which consisted of approximately $51.2 million in base consideration and $4.0 million in reimbursement for capital expenditures made by KDIL from April 1, 2011 to the closing date. AIPL also paid $7.8 million related to compensation earned from the achievement of acquisition-related milestones, of which $0.5 million was recorded as expense in the quarter ended March 31, 2013, and paid $1.6 million at closing in stamp duties to transfer title to the land and buildings at Paonta Sahib from Kilitch to AIPL. The compensation for acquisition-related milestones and other acquisition costs have been recorded within "acquisition related costs" as part of operating expenses in the Company's condensed consolidated statement of comprehensive income in the applicable periods. The BTA also contained a working capital guarantee which required KDIL to reimburse AIPL for the shortfall in the actual acquired working capital compared to the target working capital as established in the BTA. The following table sets forth the consideration paid for the Kilitch Acquisition, the acquisition-related costs incurred, and the fair values of the assets acquired and the liabilities assumed (U.S. dollar amounts in thousands):
Goodwill represents expected synergies and intangible assets that do not qualify for separate recognition. Based on a recent Indian Supreme Court ruling upholding the deductibility of goodwill for India tax purposes, the Company anticipates being able to deduct the value of goodwill for income tax purposes in India. A later Indian Supreme Court ruling raised doubt as to the tax deductibility of the cost of the non-compete agreement entered into between AIPL and the sellers. Accordingly, the Company amended its acquisition accounting to establish a deferred tax liability related to this intangible asset. The Company had initially recorded a deferred tax liability valued at $1.4 million and subsequently adjusted to $0.7 million related to intangible assets and other accrued liabilities that it does not believe will be amortizable for Indian tax purposes. This remaining deferred tax liability of $0.7 million was reversed against goodwill during 2012. For book purposes, the other intangible assets acquired are being amortized over lives of four to five years. Goodwill is not amortized for book purposes but is subject to impairment testing, per Company policy. The unaudited pro forma results presented below reflect the consolidated results of operation of the Company as if the Kilitch Acquisition had taken place at the beginning of the period presented. The pro forma results include amortization associated with the acquired intangible assets and interest on funds used for the acquisition. The unaudited pro forma financial information presented below does not reflect the impact of any actual or anticipated synergies expected to result from the acquisition. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date (amounts in thousands, except per share data):
The business acquired through the Kilitch Acquisition generated revenue of $8.5 million and a pre-tax loss of $1.8 million during the six months ended June 30, 2013. During the six months ended June 30, 2012, the acquired business generated revenue of $6.7 million and a pre-tax loss of $7.8 million. The pre-tax losses were net of acquisition-related costs of $0.5 million and $8.3 million recorded in the six month periods ended June 30, 2013 and 2012, respectively. |
BUSINESS COMBINATIONS (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 6 Months Ended | 0 Months Ended | 6 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
Kilitch Drugs (India) Limited [Member]
|
Jun. 30, 2012
Kilitch Drugs (India) Limited [Member]
|
Feb. 28, 2012
Kilitch Drugs (India) Limited [Member]
|
Jun. 30, 2013
Kilitch Drugs (India) Limited [Member]
Minimum [Member]
|
Jun. 30, 2013
Kilitch Drugs (India) Limited [Member]
Maximum [Member]
|
Feb. 28, 2012
Kilitch Drugs (India) Limited [Member]
Adjusted Fair Valuation [Member]
|
Jun. 30, 2012
Kilitch Drugs (India) Limited [Member]
Pro Forma [Member]
|
|
Business Acquisition [Line Items] | |||||||||||
Business Acquisition, Effective Date of Acquisition | Feb. 28, 2012 | ||||||||||
Business Acquisition, Date of Acquisition Agreement | Oct. 05, 2011 | ||||||||||
Total consideration paid | $ 55,200,000 | ||||||||||
Base consideration paid | 51,200,000 | ||||||||||
Reimbursement for capital expenditure | 4,000,000 | ||||||||||
Contingent consideration earned | 500,000 | 7,800,000 | |||||||||
Consideration [Abstract] | |||||||||||
Cash paid | 55,224,000 | ||||||||||
Less working capital shortfall refunded by sellers | (1,028,000) | ||||||||||
Total Purchase Price | 54,196,000 | ||||||||||
Acquisition-related costs: [Abstract] | |||||||||||
Stamp duties paid for transfer of land and buildings | 1,583,000 | ||||||||||
Acquisition-related compensation expense | 7,771,000 | ||||||||||
Due diligence, legal, travel and other acquisition-related costs | 676,000 | ||||||||||
Acquisition-related costs | 0 | 184,000 | 519,000 | 8,644,000 | 500,000 | 8,300,000 | 10,030,000 | ||||
Recognized amounts of identifiable assets acquired and liabilities assumed: [Abstract] | |||||||||||
Accounts receivable | 2,130,000 | ||||||||||
Inventory | 1,799,000 | ||||||||||
Land | 2,583,000 | ||||||||||
Buildings, plant and equipment | 8,474,000 | ||||||||||
Construction in progress | 14,231,000 | ||||||||||
Goodwill, deductible | 22,613,000 | ||||||||||
Other intangible assets, deductible | 5,908,000 | ||||||||||
Other assets | 38,000 | ||||||||||
Assumed liabilities | (2,878,000) | ||||||||||
Deferred tax liabilities | (702,000) | ||||||||||
Business combination, recognized amounts of identifiable assets acquired and liabilities assumed, net | 54,196,000 | ||||||||||
Acquired finite-lived intangible assets useful life | 4 years | 5 years | |||||||||
Revenue | 77,012,000 | 63,287,000 | 150,866,000 | 115,004,000 | 8,500,000 | 6,700,000 | 119,008,000 | ||||
Net income | 12,637,000 | 9,706,000 | 23,479,000 | 12,814,000 | 13,158,000 | ||||||
Net income per diluted share (in dollars per share) | $ 0.11 | $ 0.09 | $ 0.21 | $ 0.12 | $ 0.12 | ||||||
Pre-tax loss | $ 1,800,000 | $ 7,800,000 |
UNCONSOLIDATED JOINT VENTURE (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNCONSOLIDATED JOINT VENTURE [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Joint Venture Financial Information | The following tables set forth condensed statements of income of the Joint Venture Company for the three and six-month periods ended June 30, 2013 and 2012, as well as condensed balance sheet information as of June 30, 2013 and December 31, 2012 (in thousands):
|
ACCOUNTS RECEIVABLE ALLOWANCES (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACCOUNTS RECEIVABLE ALLOWANCES [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Trade Accounts Receivable | Net trade accounts receivable consists of the following (in thousands):
|
STOCK BASED COMPENSATION (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCK BASED COMPENSATION [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted-Average Assumptions Used in Estimating Grant Date Fair Value of Stock Options Granted | The weighted-average assumptions used in estimating the grant date fair value of the stock options granted during the three months ended June 30, 2013 and 2012, along with the weighted-average grant date fair value, was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Based Compensation Plan Activity | The table below sets forth a summary of activity within the Company's stock option plan for the six months ended June 30, 2013:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Vested Restricted Stock Activity | The following is a summary of non-vested restricted stock activity:
|
BUSINESS COMBINATIONS (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BUSINESS COMBINATIONS [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Consideration Paid for the Acquisition-Related Costs Incurred, and Fair Values of Assets acquired and Liabilities Assumed | The following table sets forth the consideration paid for the Kilitch Acquisition, the acquisition-related costs incurred, and the fair values of the assets acquired and the liabilities assumed (U.S. dollar amounts in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unaudited Pro Forma Financial Information | Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date (amounts in thousands, except per share data):
|
STOCK BASED COMPENSATION (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock-based compensation expense | $ 2,541,000 | $ 1,757,000 | $ 4,244,000 | $ 3,181,000 | |
Additional General Disclosures [Abstract] | |||||
Number of directors | 7 | 7 | |||
Stock Options and Employee Stock Purchase Plan (ESPP) [Member]
|
|||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock-based compensation expense | 2,191,000 | 1,753,000 | 3,830,000 | 3,172,000 | |
Stock Options [Member]
|
|||||
Assumptions used [Abstract] | |||||
Expected volatility (in hundredths) | 58.00% | 84.00% | 59.00% | 85.00% | |
Expected life (in years) | 4 years | 4 years | 4 years | 4 years | |
Risk-free interest rate (in hundredths) | 0.73% | 0.77% | 0.74% | 0.81% | |
Dividend yield (in hundredths) | 0.00% | 0.00% | 0.00% | 0.00% | |
Fair value per stock option (in dollars per share) | $ 6.81 | $ 7.80 | $ 6.77 | $ 7.84 | |
Forfeiture rate (in hundredths) | 8.00% | 8.00% | 8.00% | 8.00% | |
Stock-based compensation activity [Roll Forward] | |||||
Outstanding, beginning balance (in shares) | 9,727,000 | ||||
Granted (in shares) | 276,000 | ||||
Exercised (in shares) | (93,000) | 0 | (270,000) | (89,000) | |
Forfeited (in shares) | (11,000) | ||||
Outstanding, ending balance (in shares) | 9,722,000 | 9,722,000 | 9,727,000 | ||
Exercisable, ending balance (in shares) | 7,634,000 | 7,634,000 | |||
Weighted Average Exercise Price [Roll Forward] | |||||
Outstanding, beginning balance (in dollars per share) | $ 4.22 | ||||
Granted (in dollars per share) | $ 15.02 | ||||
Exercised (in dollars per share) | $ 2.51 | ||||
Forfeited (in dollars per share) | $ 10.81 | ||||
Outstanding, ending balance (in dollars per share) | $ 4.57 | $ 4.57 | $ 4.22 | ||
Exercisable, end of period (in dollars per share) | $ 2.85 | $ 2.85 | |||
Outstanding Options, Weighted Average Remaining Contractual Term | 2 years 1 month 24 days | 2 years 6 months 18 days | |||
Exercisable Options, Weighted Average Remaining Contractual Term | 1 year 8 months 19 days | ||||
Additional General Disclosures [Abstract] | |||||
Outstanding options, aggregate intrinsic value, beginning balance | 88,918,000 | ||||
Outstanding options, aggregate intrinsic value, ending balance | 87,484,000 | 87,484,000 | 88,918,000 | ||
Exercisable options, aggregate intrinsic value, ending balance | 81,491,000 | 81,491,000 | |||
Proceeds from stock options exercised | 390,000 | 0 | 677,000 | 155,000 | |
Tax deductible expenses | 950,000 | 361,000 | 3,132,000 | 643,000 | |
Restricted Stock [Member]
|
|||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock-based compensation expense | $ 350,000 | $ 4,000 | $ 414,000 | $ 8,000 | |
Additional General Disclosures [Abstract] | |||||
Granted (in shares) | 31,899 | ||||
Non-vested restricted stock activity, Number of Shares [Roll Forward] | |||||
Non-vested beginning of period (in shares) | 17,500 | ||||
Granted (in shares) | 31,899 | ||||
Forfeited (in shares) | 0 | ||||
Vested (in shares) | (15,946) | ||||
Non-vested end of period (in shares) | 33,453 | 33,453 | |||
Non-vested restricted stock activity, Weighted Average Grant Date Fair Value [Roll Forward] | |||||
Non-vested beginning of period (in dollars per share) | $ 14.63 | ||||
Granted (in dollars per share) | $ 15.36 | ||||
Forfeited (in dollars per share) | $ 0 | ||||
Vested (in dollars per share) | $ 15.36 | ||||
Non-vested end of period (in dollars per share) | $ 14.98 | $ 14.98 | |||
Restricted Stock [Member] | Director [Member]
|
|||||
Additional General Disclosures [Abstract] | |||||
Granted (in shares) | 4,557 | ||||
Common stock vested immediately upon issuance (in shares) | 2,278 | ||||
Remaining shares per director vest in one year (in shares) | 2,279 | 2,279 | |||
Non-vested restricted stock activity, Number of Shares [Roll Forward] | |||||
Granted (in shares) | 4,557 |
COMMITMENTS AND CONTINGENCIES (Details) (USD $)
|
6 Months Ended | ||
---|---|---|---|
Jun. 30, 2013
Product
|
Dec. 31, 2012
|
Dec. 22, 2011
|
|
Product Warranty Reserve [Abstract] | |||
Number of years related to warranty expiration | 10 years | ||
Product warranty liability | $ 0 | $ 1,299,000 | |
Strategic Business Agreement [Abstract] | |||
2013 | 3,664,000 | ||
2014 | 599,000 | ||
2015 | 198,000 | ||
2016 | 200,000 | ||
Total | 4,661,000 | ||
H Lundbeck AS [Member]
|
|||
Business Acquisition [Line Items] | |||
Number of NDAs off patent, branded injectable products | 3 | ||
Cash paid at closing | 45,000,000 | ||
Additional consideration owed | 15,000,000 | 15,000,000 | |
Number of products related to minimum annual purchase obligations | 2 | ||
Number of products acquired | 3 | ||
Supply purchase agreement commitment | 12,900,000 | ||
Fair value of long-term liability on a purchase obligation | $ 2,500,000 |
FINANCING ARRANGEMENTS (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FINANCING ARRANGEMENTS [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carrying Amount of Liability Component and Remaining Unamortized Debt Discount | The application of ASC 470-20 resulted in the recognition of $20,470,000 as the value for the equity component. At June 30, 2013 and December 31, 2012, the net carrying amount of the liability component and the remaining unamortized debt discount were as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expenses in Relation To Convertible Notes | For the three and six-month periods ended June 30, 2013 and 2012, the Company recorded the following expenses in relation to the Notes (in thousands):
(1) Included within "Interest expense, net" on the Condensed Consolidated Statements of Comprehensive Income. |
PROPERTY, PLANT AND EQUIPMENT (Details) (USD $)
|
6 Months Ended | ||
---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
|
Property, Plant and Equipment [Line Items] | |||
Accumulated depreciation | $ (50,757,000) | $ (47,635,000) | |
Property, plant and equipment, net | 81,033,000 | 80,679,000 | |
Depreciation | 3,200,000 | 2,000,000 | |
Outside United States [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, net | 21,900,000 | 23,700,000 | |
Land [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 2,573,000 | 2,715,000 | |
Building and Leasehold Improvements [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 44,388,000 | 43,190,000 | |
Furniture and Equipment [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 74,740,000 | 70,874,000 | |
Sub-total [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 121,701,000 | 116,779,000 | |
Property, Plant and Equipment Placed in Service, Net [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | 70,944,000 | 69,144,000 | |
Construction in Progress [Member]
|
|||
Property, Plant and Equipment [Line Items] | |||
Property, plant and equipment, gross | $ 10,089,000 | $ 11,535,000 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis Used to Measure Fair Values of Financial Instruments | The following table summarizes the basis used to measure the fair values of the Company's financial instruments as of June 30, 2013 and December 31, 2012 (amounts in thousands):
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
|
6 Months Ended | |
---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
OPERATING ACTIVITIES: | ||
Consolidated net income | $ 23,479,000 | $ 12,814,000 |
Adjustments to reconcile consolidated net income to net cash provided by operating activities: | ||
Depreciation and amortization | 6,651,000 | 5,319,000 |
Write-off and amortization of deferred financing fees | 411,000 | 388,000 |
Amortization of unfavorable contract liability | (318,000) | 0 |
Non-cash stock compensation expense | 4,244,000 | 3,181,000 |
Non-cash interest expense | 2,263,000 | 2,387,000 |
Deferred income taxes | 1,201,000 | 3,261,000 |
Excess tax benefit from stock compensation | (745,000) | (1,595,000) |
Non-cash settlement of product warranty liability | (1,299,000) | 0 |
Equity in earnings of unconsolidated joint venture | (76,000) | 0 |
Changes in operating assets and liabilities: | ||
Trade accounts receivable | (6,908,000) | (9,980,000) |
Inventories | (4,428,000) | (9,561,000) |
Prepaid expenses and other current assets | 538,000 | (1,071,000) |
Trade accounts payable | (151,000) | (2,014,000) |
Accrued expenses and other liabilities | (3,464,000) | 3,157,000 |
NET CASH PROVIDED BY OPERATING ACTIVITIES | 21,398,000 | 6,286,000 |
INVESTING ACTIVITIES: | ||
Payments for acquisitions | (513,000) | (55,224,000) |
Purchases of property, plant and equipment | (5,159,000) | (12,253,000) |
NET CASH USED IN INVESTING ACTIVITIES | (5,672,000) | (67,477,000) |
FINANCING ACTIVITIES: | ||
Excess tax benefit from stock compensation | 745,000 | 1,595,000 |
Proceeds under stock option and stock purchase plans | 1,265,000 | 523,000 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,010,000 | 2,118,000 |
Effect of exchange rate changes on cash and cash equivalents | (105,000) | (479,000) |
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 17,631,000 | (59,552,000) |
Cash and cash equivalents at beginning of period | 40,781,000 | 83,962,000 |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 58,412,000 | 24,410,000 |
SUPPLEMENTAL DISCLOSURES: | ||
Amount paid for interest | 2,152,000 | 2,141,000 |
Amount paid for income taxes | $ 11,936,000 | $ 5,819,000 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation: The accompanying condensed consolidated financial statements include the accounts of Akorn, Inc. and its wholly-owned domestic and foreign subsidiaries. All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of Akorn India Private Limited ("AIPL") have been translated from Indian rupees to U.S. dollars based on the currency translation rates in effect during the period presented or as of the date of consolidation, as applicable. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Chargebacks and Rebates: The Company enters into contractual agreements with certain third parties such as hospitals and group-purchasing organizations to sell certain products at predetermined prices. The parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product. The Company reduces gross sales and increases the chargeback allowance by the estimated chargeback amount for each product sold to a wholesaler. The Company reduces the chargeback allowance when it processes a request for a chargeback from a wholesaler. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company's provision for chargebacks is fully reserved for at the time when sales revenues are recognized. Management obtains certain wholesaler inventory reports to aid in analyzing the reasonableness of the chargeback allowance. The Company assesses the reasonableness of its chargeback allowance by applying the historical product chargeback percentage to the quantities of inventory on hand per the wholesaler inventory reports and an estimate of in-transit inventory that is not reported on the wholesaler inventory reports at the end of the period. The Company estimates the percentage amount of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a six-quarter trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends or other information indicates that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change. The Company used an estimate of 90.0% during the quarter and six months ended June 30, 2013 and 98.5% during the quarter and six months ended June 30, 2012. Sales Returns: Certain of the Company's products are sold subject to terms that allow the customer the right to return the product within specified periods and guidelines for a variety of reasons, including but not limited to, pending expiration dates. Provisions are made at the time of sale based upon tracked historical experience, by customer in some cases. One-time historical factors or pending new developments that would impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the balance required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the wholesaler's inventory information to assess the amount of unconsumed product that may result in a sales return to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the end-user pull through for sales of the Company's products and ultimately impact the level of sales returns. Actual returns experience and trends are factored into the Company's estimates each quarter as market conditions change. Actual returns processed can vary materially from period to period. Allowance for Coupons and Promotions: The Company issues coupons from time to time that are redeemable against our TheraTears® eye care products. Upon release of coupons into the market, the Company records an estimate of the dollar value of coupons expected to be redeemed. This estimate is based on historical experience and is adjusted as needed based on actual redemptions. In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales of its products. Upon receiving confirmation that a promotion was run, the Company accrues an estimate of the dollar amount expected to be owed back to the retailer. This estimate is trued up upon receipt of the invoice from the retailer. For our treatment of advertising and promotional expenses paid to customers, we referred to guidance contained within ASC 605-50, Customer Payments and Incentives. Inventories: Inventories are stated at the lower of cost (average cost method) or market (see Note 6 — "Inventories"). The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory with a carrying value in excess of its net realizable value or "NRV". For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow moving based upon recent sales activity. The Company also analyzes its raw material and component inventory for slow moving items. The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval. The Company considers the shelf life of the product in relation to the product timeline for approval. Income taxes: Deferred income tax assets and liabilities are recognized for the tax effects of temporary differences between the financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the recognized deferred tax assets to the amount that is more likely than not to be realized. Fair Value of Financial Instruments: The Company applies ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC Topic 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company's principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC Topic 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions based on market data and the entity's judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances. The valuation hierarchy is composed of three categories. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described below:
The following table summarizes the basis used to measure the fair values of the Company's financial instruments as of June 30, 2013 and December 31, 2012 (amounts in thousands):
The carrying amount of the purchase consideration payable was initially determined based on the terms of the underlying contracts and the Company's subjective evaluation of the likelihood of the additional purchase consideration becoming payable. The purchase consideration payable is related to the Company's obligation to pay additional consideration of $15.0 million related to the acquisition of selected assets from H. Lundbeck A/S ("Lundbeck") effected on December 22, 2011. The underlying obligation, which is payable three years after the acquisition date, is long-term in nature, and therefore was discounted to present value based on an assumed discount rate. The fair value of the liability is based upon the likelihood of achieving the underlying revenue targets and a derived cost of debt based on the remaining term. Therefore, the liability is sensitive to changes in the market rate of interest. The Company initially determined that there was a 100% likelihood of the purchase consideration ultimately becoming payable, and reaffirmed that this was still the Company's determination as of both December 31, 2012 and June 30, 2013. Should subjective and objective evidence lead the Company to change this assessment, an adjustment to the carrying value of the liability would be recorded as "other income" in the Company's condensed consolidated statements of comprehensive income. At December 31, 2012, the Company performed an evaluation of the fair value of this liability based on utilizing significant unobservable inputs to derive a discount rate of 2.75%, and determined that the appropriate discounted value was $14,208,000. At June 30, 2013, the Company performed an evaluation of the fair value of this liability based on utilizing significant unobservable inputs to derive a discount rate of 2.52%, and determined that the appropriate discounted value was approximately $14,451,000. The $243,000 change in fair value from December 31, 2012 to June 30, 2013 was recorded under the caption "interest expense, net" within the Company's condensed consolidated statement of comprehensive income for the six months ended June 30, 2013. As of June 30, 2013 and December 31, 2012, the Company was carrying long-term investments valued at $10,311,000 and $10,299,000, respectively. The underlying assets are cost-basis investments for which fair value is not readily determinable. Business Combinations: Business combinations are accounted for under ASC 805, Business Combinations, using the acquisition method of accounting. The acquisition method of accounting requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Under the acquisition method of accounting, the Company will identify the acquirer and the closing date and apply applicable recognition principles and conditions. Acquisition-related costs are costs the Company incurs to effect a business combination. The Company accounts for acquisition-related costs as expenses in the periods in which the costs are incurred. |
ACCOUNTS RECEIVABLE ALLOWANCES
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACCOUNTS RECEIVABLE ALLOWANCES [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACCOUNTS RECEIVABLE ALLOWANCES | NOTE 5 — ACCOUNTS RECEIVABLE ALLOWANCES The nature of the Company's business inherently involves, in the ordinary course, significant amounts and substantial volumes of transactions and estimates relating to allowances for product returns, chargebacks, rebates, doubtful accounts and discounts given to customers. This is a natural circumstance of the pharmaceutical industry and not specific to the Company and inherently lengthens the final net collections process. Depending on the product, the end-user customer, the specific terms of national supply contracts and the particular arrangements with the Company's wholesaler customers, certain rebates, chargebacks and other credits are deducted from the Company's accounts receivable. The process of claiming these deductions depends on wholesalers reporting to the Company the amount of deductions that were earned under the terms of the respective with the end-user customer (which in turn depends on which end-user customer, each having its own pricing arrangement might be entitled to a particular deduction). This process can lead to partial payments against outstanding invoices as the wholesalers take the claimed deductions at the time of payment. The provisions for the following customer reserves are reflected in the accompanying financial statements as reductions of revenues in the statements of comprehensive income with the exception of the provision for doubtful accounts which is reflected as part of selling, general and administrative expense. The ending reserve amounts are included in trade accounts receivable, net in the Company's condensed consolidated balance sheets. Net trade accounts receivable consists of the following (in thousands):
For the three month periods ended June 30, 2013 and 2012, the Company recorded chargeback and rebate expense of $42.9 million and $23.0 million, respectively. For the six month periods ended June 30, 2013 and 2012, the Company recorded chargeback and rebate expense of $86.7 million and $45.0 million, respectively. For the three month periods ended June 30, 2013 and 2012, the Company recorded provisions for product returns of $0.5 million and $1.6 million, respectively. For the six month periods ended June 30, 2013 and 2012, the Company recorded provisions for product returns of $1.7 million and $3.0 million, respectively. For the three month periods ended June 30, 2013 and 2012, the Company recorded provisions for cash discounts of $1.9 million and $1.4 million, respectively. For the six month periods ended June 30, 2013 and 2012, the Company recorded provisions for cash discounts of $3.9 million and $2.6 million, respectively. The current period increases in chargebacks and rebates and cash discounts were related to the increase in sales within the Ophthalmic and Hospital drugs & injectables segments. The current period decrease in the provisions for product returns was due to a decline in the anticipated rate of future product returns based on historical returns experience. |
STOCK BASED COMPENSATION
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCK BASED COMPENSATION [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCK BASED COMPENSATION | NOTE 3 — STOCK BASED COMPENSATION Stock-based compensation cost is estimated at grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the grant date fair value of stock options. Determining the assumptions that enter into the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its common stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. treasury securities in effect during the quarter in which the options were granted. The dividend yield reflects historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises the estimate in subsequent periods, if necessary, if actual forfeitures differ from initial estimates. For the three and six month periods ended June 30, 2013, the Company recorded total stock-based compensation expense of $2,541,000 and $4,244,000, respectively, of which $2,191,000 and $3,830,000 was related to stock options. In the prior year three and six month periods ended June 30, 2012, the Company recorded total stock-based compensation expense of $1,757,000 and $3,181,000, respectively, of which $1,753,000 and $3,172,000 was related to stock options. The remaining stock-based compensation expense not related to stock options was related to the vesting of restricted stock awards. The Company uses the single-award method for allocating compensation cost related to stock options to each period. The weighted-average assumptions used in estimating the grant date fair value of the stock options granted during the three months ended June 30, 2013 and 2012, along with the weighted-average grant date fair value, was as follows:
The table below sets forth a summary of activity within the Company's stock option plan for the six months ended June 30, 2013:
The aggregate intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company's common stock as of the date indicated and the exercise price of the stock options. During the three and six month periods ended June 30, 2013, 93,000 and 270,000 stock options were exercised resulting in cash payments to the Company of $390,000 and $677,000, respectively. These stock option exercises generated tax-deductible expenses totaling $950,000 and $3,132,000, respectively. During the three and six month periods ended June 30, 2012, zero and 89,000 stock options were exercised resulting in cash payments to the Company of zero and $155,000, respectively. These option exercises generated tax-deductible expenses totaling $361,000 and $643,000, respectively. The Company also may grant restricted stock awards to certain employees and members of its Board of Directors ("Directors"). Restricted stock awards are valued at the closing market price of the Company's common stock on the day of grant and the total value of the award is recognized as expense ratably over the vesting period of the grants. The Company granted 4,557 restricted shares to each of its seven Directors during the six months ended June 30, 2013, of which 2,278 shares per Director vested immediately upon issuance and the remaining 2,279 shares per Director will vest on the one-year anniversary of grant. The Company did not grant restricted stock awards during the six months ended June 30, 2012. During the three and six month periods ended June 30, 2013, the Company recognized compensation expense of $350,000 and $414,000, respectively, related to unvested restricted stock awards. During the prior year three and six month periods ended June 30, 2012, the Company recognized compensation expense of $4,000 and $8,000, respectively, related to unvested restricted stock awards. The following is a summary of non-vested restricted stock activity:
|
ACCOUNTS RECEIVABLE ALLOWANCES (Details) (USD $)
|
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
|
Accounts Receivable, Net, Current [Abstract] | |||||
Gross accounts receivable | $ 79,696,000 | $ 79,696,000 | $ 74,855,000 | ||
Less: | |||||
Chargebacks and rebates | (11,515,000) | (11,515,000) | (13,452,000) | ||
Products returns | (8,359,000) | (8,359,000) | (8,409,000) | ||
Discount and allowances | (1,616,000) | (1,616,000) | (1,362,000) | ||
Advertising and promotions | (468,000) | (468,000) | (585,000) | ||
Doubtful accounts | (31,000) | (31,000) | (30,000) | ||
Trade accounts receivable, net | 57,707,000 | 57,707,000 | 51,017,000 | ||
Chargeback and rebate expense | 42,900,000 | 23,000,000 | 86,700,000 | 45,000,000 | |
Provision for product returns | 500,000 | 1,600,000 | 1,700,000 | 3,000,000 | |
Provision for cash discounts | $ 1,900,000 | $ 1,400,000 | $ 3,900,000 | $ 2,600,000 |
INVENTORIES (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORIES [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | The components of inventories are as follows (in thousands):
|
EARNINGS PER COMMON SHARE (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EARNINGS PER COMMON SHARE [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Earnings Per Share Data | The Company's potentially dilutive securities consist of: (i) vested and unvested stock options that are in-the-money, (ii) warrants that are in-the-money, (iii) unvested restricted stock awards ("RSAs"), and (iv) shares issuable on conversion of convertible notes. Information about the computation of basic and diluted earnings per share is detailed below (in thousands, except per share data):
(1) Shares issuable upon conversion of convertible notes is based on the assumption that the Company would repay the principal of the notes in cash and pay any incremental value in shares of common stock. |
INCOME TAXES (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INCOME TAXES [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Provision | The following table sets forth information about the Company's income tax provision for the periods indicated (dollar amounts in thousands):
|